These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 20015866

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta.
    Alt A, Lammens K, Chiocchini C, Lammens A, Pieck JC, Kuch D, Hopfner KP, Carell T.
    Science; 2007 Nov 09; 318(5852):967-70. PubMed ID: 17991862
    [Abstract] [Full Text] [Related]

  • 4. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
    Bassett E, Vaisman A, Havener JM, Masutani C, Hanaoka F, Chaney SG.
    Biochemistry; 2003 Dec 09; 42(48):14197-206. PubMed ID: 14640687
    [Abstract] [Full Text] [Related]

  • 5. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
    Plooy AC, van Dijk M, Lohman PH.
    Cancer Res; 1984 May 09; 44(5):2043-51. PubMed ID: 6538808
    [Abstract] [Full Text] [Related]

  • 6. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF, Le Pla RC, Jones GD, Thomas AL, Farmer PB.
    Chem Res Toxicol; 2010 Aug 16; 23(8):1313-21. PubMed ID: 20666396
    [Abstract] [Full Text] [Related]

  • 7. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
    Chaney SG, Campbell SL, Bassett E, Wu Y.
    Crit Rev Oncol Hematol; 2005 Jan 16; 53(1):3-11. PubMed ID: 15607931
    [Abstract] [Full Text] [Related]

  • 8. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG.
    Biochemistry; 1999 Aug 24; 38(34):11026-39. PubMed ID: 10460158
    [Abstract] [Full Text] [Related]

  • 9. Frequencies of mutagenic translesion DNA synthesis over cisplatin-guanine intra-strand crosslinks in lacZ plasmids propagated in human cells.
    Fujikawa Y, Kawanishi M, Kuraoka I, Yagi T.
    Mutat Res Genet Toxicol Environ Mutagen; 2014 Aug 24; 770():23-8. PubMed ID: 25344160
    [Abstract] [Full Text] [Related]

  • 10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 11. p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells.
    Bhana S, Hewer A, Phillips DH, Lloyd DR.
    Mutagenesis; 2008 Mar 15; 23(2):131-6. PubMed ID: 18267949
    [Abstract] [Full Text] [Related]

  • 12. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J, Novakova O, Farrell N, Brabec V.
    Biochemistry; 2003 Jan 28; 42(3):792-800. PubMed ID: 12534292
    [Abstract] [Full Text] [Related]

  • 13. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts.
    Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M.
    Cancer Res; 2004 Sep 15; 64(18):6469-75. PubMed ID: 15374956
    [Abstract] [Full Text] [Related]

  • 14. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG.
    Cancer Res; 1994 Jul 01; 54(13):3500-5. PubMed ID: 8012973
    [Abstract] [Full Text] [Related]

  • 15. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
    Comess KM, Burstyn JN, Essigmann JM, Lippard SJ.
    Biochemistry; 1992 Apr 28; 31(16):3975-90. PubMed ID: 1314653
    [Abstract] [Full Text] [Related]

  • 16. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
    Lippert B.
    Met Ions Biol Syst; 1996 Apr 28; 33():105-41. PubMed ID: 8742842
    [Abstract] [Full Text] [Related]

  • 17. The thermodynamics of translesion DNA synthesis past major adducts of enantiomeric analogues of antitumor cisplatin.
    Malina J, Novakova O, Natile G, Brabec V.
    Chem Asian J; 2012 May 28; 7(5):1026-31. PubMed ID: 22374916
    [Abstract] [Full Text] [Related]

  • 18. The N2-ethylguanine and the O6-ethyl- and O6-methylguanine lesions in DNA: contrasting responses from the "bypass" DNA polymerase eta and the replicative DNA polymerase alpha.
    Perrino FW, Blans P, Harvey S, Gelhaus SL, McGrath C, Akman SA, Jenkins GS, LaCourse WR, Fishbein JC.
    Chem Res Toxicol; 2003 Dec 28; 16(12):1616-23. PubMed ID: 14680376
    [Abstract] [Full Text] [Related]

  • 19. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.
    Hollis LS, Sundquist WI, Burstyn JN, Heiger-Bernays WJ, Bellon SF, Ahmed KJ, Amundsen AR, Stern EW, Lippard SJ.
    Cancer Res; 1991 Apr 01; 51(7):1866-75. PubMed ID: 2004370
    [Abstract] [Full Text] [Related]

  • 20. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
    Ahmad S.
    Chem Biodivers; 2010 Mar 01; 7(3):543-66. PubMed ID: 20232326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.